Welcome to ActoGeniX

ActoGeniX is a biopharmaceutical company, focused on the development and commercialization of a new generation of biological drugs; ActoBiotics™.

About ActoGeniX

ActoGeniX’s mission is to develop and commercialize innovative biological therapies, to improve the treatment and well-being of patients with gastrointestinal, immunological and metabolic diseases.

 

More about ActoGeniX →

About ActoBiotics™

ActoBiotics™ represent a novel concept for oral administration of therapeutic proteins, and are designed to be safer and more effective than injectable biopharmaceuticals. This novel class of biopharmaceuticals has the potential to treat a broad range of severe diseases.

 

More about ActoBiotics™ →

Video: What are ActoBiotics™?

Watch our introduction video on ActoBiotiocs by clicking on the image.

 

Recent Updates

Please click here for the latest news and headlines from ActoGeniX.

Show all news & events

BioEquity Europe 2013

05/22/2013

May 22-23, 2013
Stockholm, Sweden

http://www.ebdgroup.com/bee

ActoGeniX closes EUR 10.7 million financing round

04/18/2013

Ghent, Belgium – April 18th, 2013

ActoGeniX, a clinical stage biopharmaceutical company, successfully closed a Series B equity financing round, raising EUR 10.7 million (USD 14 million). This financing round was led by new investor Saffelberg Investments (Belgium). ActoGeniX’s founders

Knowledge for Growth – Presentation

03/01/2013

May 30, 2013
ICC Ghent

http://knowledgeforgrowth.be/